Checkmate Pharmaceuticals, Inc.

Who: Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics What: Regeneron will acquire Decibel Therapeutics, its partner on the development of gene therapies for hearing loss since 2017. Why:

Regeneron Pharmaceuticals, Inc. has set a goal to become a leading player in the competitive immuno-oncology space, and has now secured full ownership of a cornerstone asset in that strategy – the PD

Regeneron Pharmaceuticals, Inc. will acquire Checkmate Pharmaceuticals, Inc. in a $250m deal, marking the fourth biotech deal this month which hints at increasing appetite in investment even as the

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca Offloads Phase III-Ready Su